Novavax aims to make one billion COVID-19 vaccine doses
Novavax is buying a manufacturing plant from privately held Serum Institute of India, the world's largest vaccine company by volume, as the US company aims to make 1 billion doses of its COVID-19 vaccine candidate next year.
The U.S. company said on Wednesday it would buy Czech Republic-based Praha Vaccines, a unit of India’s Cyrus Poonawalla Group, which owns the Serum Institute, for $ 167 million in cash.
Novavax is one of several companies involved in the race to develop a vaccine for COVID-19, a novel disease caused by the corona virus, for which there is no current treatment or vaccine and about 350, 000 people have died.
Although experts predict that the shot will take 12-18 months to develop, world leaders see vaccines as the only way to restart their stagnant economy after months of locks, Goes.
0 Comments